- Biocon reported a net income of 845 million rupees for the second quarter of 2025, a significant improvement from a loss of 160 million rupees in the previous year.
- The company’s revenue increased by 20% year-on-year to 43 billion rupees, exceeding the estimated 41.83 billion rupees.
- Revenue from generics increased by 24% year-on-year to 7.74 billion rupees, surpassing the estimate of 7.26 billion rupees.
- Biosimilars revenue grew by 25% year-on-year, reaching 27.21 billion rupees, above the projected 26.22 billion rupees.
- Revenue from research services rose by 2.2% year-on-year to 9.11 billion rupees, though it fell short of the 9.56 billion rupees estimate.
- Total costs for Biocon rose by 19% year-on-year, amounting to 42.1 billion rupees.
- Finance costs increased by 20% year-on-year to 2.72 billion rupees, higher than the anticipated 2.26 billion rupees.
- Key actions include the early full redemption of 5 billion rupees in non-convertible debentures and acquiring CCDs of Biocon Biologics from Edelweiss.
- Biocon issued 3 billion rupees in compulsorily convertible debentures for Biocon Biologics and approved the issuance of commercial papers up to 5.5 billion rupees.
- Market analyst ratings currently list 10 buys, 3 holds, and 5 sells for Biocon.
Biocon Ltd on Smartkarma
On Smartkarma, analyst Akshat Shah‘s coverage of Biocon Ltd‘s recent Qualified Institutional Placement (QIP) focuses on the company’s initiative to raise approximately US$520 million to primarily reduce its debt burden. The floor price set for the QIP stands at INR 323.2 per share, reflecting a 9.5% discount to the last closing price. Biocon Ltd, listed as BIOS IN, has diligently navigated through necessary approvals, garnering media attention throughout the process. Shah’s report delves into the strategic implications of the QIP within the context of Biocon Ltd‘s capital structure, providing valuable insights for investors.
A look at Biocon Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
The long-term outlook for Biocon Ltd looks promising based on the Smartkarma Smart Scores. With a strong Value score of 4, the company is deemed to be undervalued in the market, indicating good potential for future growth. Additionally, Biocon scores well in Momentum with a score of 4, suggesting positive price trends and investor sentiment.
Although the Dividend score is moderate at 2, the company shows steady Growth potential with a score of 3, reflecting its ability to expand and improve earnings. The Resilience score of 3 indicates that Biocon has a sturdy business model that can weather economic uncertainties. Overall, Biocon Ltd., a leading biotechnology enterprise with a diverse product portfolio, seems well-positioned for long-term success and value creation for investors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
